BG
SRPT icon

Bellevue Group’s Sarepta Therapeutics SRPT Stock Holding History

Bellevue Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-149,113
Closed -$9.52M – 152
2025
Q1 		$9.52M Sell
149,113
-22,204
-13% -$2.34M 0.21% 77
2024
Q4 		$20.8M Sell
171,317
-173,031
-50% -$21.2M 0.4% 61
2024
Q3 		$43M Buy
344,348
+92,027
+36% +$12.7M 0.7% 39
2024
Q2 		$39.9M Buy
252,321
+800
+0.3% +$103K 0.65% 44
2024
Q1 		$32.6M Buy
251,521
+14,235
+6% +$1.74M 0.5% 61
2023
Q4 		$22.9M Sell
237,286
-4,466
-2% -$428K 0.35% 71
2023
Q3 		$29.3M Buy
241,752
+41,532
+21% +$4.69M 0.47% 63
2023
Q2 		$22.9M Sell
200,220
-446,394
-69% -$57.6M 0.33% 70
2023
Q1 		$89.1M Sell
646,614
-46,595
-7% -$6.04M 1.29% 20
2022
Q4 		$89.8M Sell
693,209
-62,689
-8% -$7.26M 1.19% 24
2022
Q3 		$83.6M Sell
755,898
-383,557
-34% -$38.7M 1.2% 27
2022
Q2 		$85.4M Sell
1,139,455
-11,704
-1% -$861K 1.21% 24
2022
Q1 		$89.9M Buy
1,151,159
+324,418
+39% +$24.8M 1.04% 33
2021
Q4 		$74.4M Buy
826,741
+257,573
+45% +$22M 0.77% 44
2021
Q3 		$52.6M Buy
+569,168
New +$43.8M 0.53% 61
2021
Q2 		– Sell
-20,300
Closed -$1.51M – 223
2021
Q1 		$1.51M Hold
20,300
– – 0.02% 149
2020
Q4 		$3.46M Hold
20,300
– – 0.04% 132
2020
Q3 		$2.85M Hold
20,300
– – 0.04% 138
2020
Q2 		$3.25M Buy
20,300
+300
+2% +$40.8K 0.05% 128
2020
Q1 		$1.96M Buy
20,000
+4,500
+29% +$514K 0.04% 129
2019
Q4 		$2M Buy
+15,500
New +$1.56M 0.03% 131
2019
Q2 		– Sell
-9,100
Closed -$1.08M – 214
2019
Q1 		$1.08M Sell
9,100
-3,600
-28% -$463K 0.06% 125
2018
Q4 		$1.39M Sell
12,700
-400
-3% -$50K 0.09% 105
2018
Q3 		$2.12M Buy
+13,100
New +$1.79M 0.13% 103

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Bellevue Group's SRPT Position: Q2 2025 in Review

Bellevue Group sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 149,113 shares — an estimated $9.52M sold.

Bellevue Group first reported a position in SRPT in Q3 2018 and held it in 24 quarters. The position peaked at $89.9M in Q1 2022. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Bellevue Group reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bellevue Group sold 149,113 Sarepta Therapeutics shares in Q2 2025, an estimated $9.52M.
  • Bellevue Group first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 24 quarters.
  • Bellevue Group's Sarepta Therapeutics position peaked at $89.9M in Q1 2022.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.